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The hepatitis C virus (HCV) polymerase is required
for replication of the viral genome and is a key target for
therapeutic intervention against HCV. We have deter-
mined the crystal structures of the HCV polymerase
complexed with two indole-based allosteric inhibitors at
2.3- and 2.4-Å resolution. The structures show that these
inhibitors bind to a site on the surface of the thumb
domain. A cyclohexyl and phenyl ring substituents,
bridged by an indole moiety, fill two closely spaced
pockets, whereas a carboxylate substituent forms a salt
bridge with an exposed arginine side chain. Interest-
ingly, in the apoenzyme, the inhibitor binding site is
occupied by a small -helix at the tip of the N-terminal
loop that connects the fingers and thumb domains.
Thus, these molecules inhibit the enzyme by preventing
formation of intramolecular contacts between these two
domains and consequently precluding their coordinated
movements during RNA synthesis. Our structures iden-
tify a novel mechanism by which a new class of allosteric
inhibitors inhibits the HCV polymerase and open the
way to the development of novel antiviral agents against
this clinically relevant human pathogen.
The hepatitis C virus (HCV)1 is a small positive-strand RNA
virus responsible for a considerable proportion of acute and
chronic hepatitis in humans (1, 2). It is estimated that more
than 170 million people worldwide are infected by this virus (3).
There is no vaccine available for HCV, and the current therapy,
based on interferon and ribavirin, is poorly tolerated and of
limited efficacy. Therefore, there are intense research efforts
toward the development of new drugs targeting essential HCV
enzymes and in particular the polymerase. The HCV nonstruc-
tural protein 5B (NS5B) is the RNA-dependent RNA polymer-
ase (RdRp) responsible for replication of the viral genome.
NS5B can initiate RNA synthesis by two different mechanisms:
primer-independent initiation from the 3 terminus of the viral
genome, also known as de novo initiation (4, 5), and primer-de-
pendent initiation using either DNA or RNA as primers (6).
The de novo synthesis is likely used during virus replication in
infected cells (7).
The three-dimensional structures of soluble forms of the
HCV polymerase genotype 1b, C21 and C55, lacking the last
21 and 55 C-terminal residues, respectively, have been re-
ported (8–10). These structures revealed a classical “right
hand” shape formed by the palm, thumb, and fingers domains
as initially defined in the Klenow fragment of Escherichia coli
DNA polymerase I (11) and showed the presence of an exten-
sion in the fingers, the so-called fingertip subdomain, contain-
ing two loops, 1 and 2 (secondary structure nomenclature
according to Ref. 9), which anchor the fingers to the thumb. As
a result, the polymerase has a relatively closed and spherical
appearance, and the active site cavity, to which the RNA tem-
plate and the NTP substrates have access via two positively
charged tunnels, is completely encircled. Structural studies
have shown that other viral RdRps, such as those of poliovirus
(12, 13), human rhinovirus (14, 15), bovine viral diarrhea virus
(16), rabbit hemorrhagic disease virus (17), reovirus (18), and
bacteriophage 6 (19), have the same global architecture and a
similar closed conformation. Crystal structures of NS5B bound
to a short RNA template or to NTPs have also been solved (20,
21). Interestingly, in all these structures, ligand binding oc-
curred without rearrangements in the enzyme domains. More-
over, the structure of the NS5B-GTP complex showed that, in
addition to the active site, GTP can also bind to an exposed site
on the thumb domain in close proximity to the tip of the
fingertip 1 loop (21). This external GTP site, 30 Å away from
the polymerase catalytic center, was proposed to exert a regu-
latory activity by modulating the interactions between the fin-
gers and thumb domains during RNA synthesis. Recently, the
structure of the HCV polymerase genotype 2a (this enzyme
shares 70% sequence identity with the 1b polymerase) was
reported (22). This study revealed two conformations of the
enzyme: closed, similar to the apo1b polymerase structure, and
a more opened structure. Interestingly, in the opened confor-
mation the tip of the fingertip 1 loop, which is -helical in the
closed conformation of the polymerase, moved away from the
thumb domain and adopted a -hairpin-like structure.
The discovery and characterization of a number of structur-
ally diverse non-nucleoside inhibitors (NNIs) of the HCV poly-
merase have been reported (22–26). These molecules inhibited
the polymerase at a stage preceding the elongation step and
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non-competitively with RNA template or NTPs (24, 25). De-
spite these common features in the mechanism of inhibition,
structural, genetic, and biochemical evidence suggest that HCV
NNIs bind to different sites on the polymerase. Specifically,
crystallographic studies indicate that inhibitors based on thio-
phene, phenylalanine, or dihydropyranone scaffolds bind in a
hydrophobic cleft in the thumb domain near the C terminus of
the polymerase and 10–15 Å from the external GTP site (21–
23). Conversely, a combination of genetic and biochemical data
suggests that a second group of NNIs, comprising compounds
based on the structurally related benzimidazole and indole
core, binds at the exposed GTP site (24, 25). In agreement with
this hypothesis, resistance to these inhibitors arises through
mutation of Pro-495, a residue involved in the interaction with
the external GTP molecule, and enzyme binding and inhibition
are antagonized by GTP (24). Benzimidazole- and indole-de-
rived NNIs have provided encouraging results as anti-HCV
agents. In a recent study indole-based inhibitors were shown to
be devoid of off-target activities and presented encouraging
pharmacokinetic profiles in preclinical animal studies (27). In
addition, a benzimidazole polymerase inhibitor has entered
into Phase I/II clinical trials (28).
Here we describe the crystal structures of the HCV polym-
erase in complex with two indole-derived NNIs. These struc-
tures reveal a novel inhibitory binding site in the polymerase
and open the way to the design of new NNIs for treatment of
HCV infection. Furthermore, our structures suggest a mecha-
nism of inhibition, with the inhibitor displacing part of the
fingertip loop anchoring the fingers domain to the thumb do-
main, which may also be relevant for the inhibition of other
viral RdRps.
MATERIALS AND METHODS
Protein Expression and Purification—A variant of HCV NS5B (gen-
otype 1b, strain BK) lacking 55 C-terminal residues (C55) and a P495L
point mutant (24) have been expressed and purified as detailed below.
Protein overexpression was performed by induction of mid-log phase
BL21 DE3 E. coli cells with 0.4 mM isopropyl-1-thio--D-galactopyrano-
side for 22 h at 18 °C in LB medium. Harvested bacteria were resus-
pended in ice-cold lysis buffer (20 mM Tris-HCl, pH 7.5, 300 mM NaCl,
20% glycerol, 0.2% -octylglucoside, 1 mM EDTA, 10 mM dithiothreitol
(DTT), and CompleteTM EDTA-free protease inhibitor mixture tablets)
and lysed with a cell disruptor (Costant System). Lysate was incubated
with DNase I (5 units/ml) in the presence of 10 mM MgCl2 and clarified
by centrifugation at 35,000  g for 1 h. The supernatant was loaded
onto a heparin column pre-equilibrated with buffer A-Hep (20 mM
Tris-HCl, pH 7.5, 300 mM NaCl, 20% glycerol, 0.2% -octylglucoside, 1
mM EDTA, 10 mM DTT) at 4 °C, and the protein was eluted with a salt
gradient in 700 mM NaCl. Protein fractions were pooled and diluted
with the A-Hep buffer without NaCl to reach 150 mM NaCl and loaded
onto an ion-exchange Resource S column pre-equilibrated in A-S buffer
(20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20% glycerol, 0.2% -octylglu-
coside, 1 mM EDTA, and 10 mM DTT). The column was washed in buffer
with 300 mM NaCl, and the protein was subjected to a linear gradient
from 300 mM to 1 M NaCl. The protein elutes at 500 mM NaCl.
Fractions were loaded onto a Sephadex G75 gel filtration column equil-
ibrated in 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 20% glycerol, 0.2%
-octylglucoside, 1 mM EDTA, and 10 mM DTT. The protein was ana-
lyzed by electrospray ionization-mass spectrometry and confirmed to be
95% pure, with an experimental mass of 59,555 Da (theoretical mass
59,561 Da). The full-length NS5B protein and the C21 protein, a NS5B
variant with the last 21 C-terminal residues deleted, were expressed
and purified as described previously (29, 30). Details of the polymerase
activity assay and replicon analysis have been described in Ref. 24.
Crystallization and Data Collection—NS5B-C55 crystals were
grown as described previously (9). Inhibitor soakings were performed by
transferring crystals in a solution containing 100 mMMES, pH 6.0, 14%
polyethylene glycol 8,000, 14% 2-propanol, 10 mM DTT, 10 mM MnCl2,
and 2.5 mM of compound 1 or 2. Soaking was performed for only 20–30
min as crystals had the tendency to crack 40–60 min after inhibitor
addition. Crystals were then transferred for 1 min to a cryoprotectant
solution containing 100 mM MES, pH 6.0, 14% polyethylene glycol
8,000, 14% 2-propanol, 18% 2-methyl-2,5-pentanediol, 10 mM DTT, 5
mM MnCl2, and 1.25 mM compound 1 or 2. Diffraction data were col-
lected at 100 K from cryo-cooled crystals at the ID14-H1 beam-line at
the European Synchrotron Radiation Facility (Grenoble, France). Data
were processed with MOSFLM and scaled with SCALA (31). Data
collection statistics are summarized in supplemental Table II. Further
data processing and analysis were performed with the CCP4 suite of
programs (31).
Structure Determination and Refinement—Crystals of the apoprotein
grew in space group P212121 with two molecules in the asymmetric unit
(9), but after soaking, the space group shifted to P21212 with one
molecule in the asymmetric unit (supplemental Table II), similar to
what was described for the structure of the polymerase-GTP complex
(21). The two structures of the C55 polymerase-inhibitor complexes
were solved by the molecular replacement method with the program
AMoRe from CCP4 (31) using the structure of the apoC55 as a search
model (9). Model building with QUANTA (Accelrys, San Diego, CA) and
refinement with REFMAC from CCP4 (31), using a maximum likeli-
hood target, resulted in the final models (supplemental Table II). No
electron density was present for residues 22–35, 148–152, and 532–536,
which were therefore excluded from the refinement. Both structures
satisfy all the criteria set by the program PROCHECK (32), and all
amino acids lie in allowed regions of the Ramachandran plot.
RESULTS AND DISCUSSION
Inhibition of HCV Polymerase—The key pharmacophore el-
ements of the allosteric inhibitors used in this study include a
central scaffold of a 6,5-fused ring system, which proved to be
optimal (27), an acid, a cyclohexyl and an aryl substituent
(Table I). The only difference between the two inhibitors re-
sides in the indole N-acetyl substituent. Both compounds in-
hibited the purified enzyme with IC50 values in the low nM
range and subgenomic HCV RNA replication in the sub-M
range (Table I). Inhibition was independent of the form of
recombinant polymerase used as both full-length and C-termi-
nally truncated C21 and C55 were inhibited with similar
IC50 values (for compound 2 the IC50 values for the full-length
and C21 enzymes were 22 and 100 nM, respectively).
Inhibitor Binding and Polymerase Conformational Change—
The crystal structures of the C55 polymerase in complex with
compound 1 (2.3-Å resolution) and compound 2 (2.4-Å resolu-
tion) were obtained by soaking procedures. In both cases, anal-
TABLE I
Potency of compounds 1 and 2
* Compound 1, 3-cyclohexyl-1-(2-morpholin-4-yl-2-oxoethyl)-2-
phenyl-1H-indole-6-carboxylic acid; compound 2, 3-cyclohexyl-1-(2-
{methyl[(1-methylpiperidin-3-yl)methyl]amino)-2-oxoethyl)-2-phenyl-
1H-indole-6-carboxylic acid.
† N.A., not active up to 10 M.
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ysis of the initial electron density map showed clearly defined
electron density for the inhibitor (supplemental Fig. 6). How-
ever, different from what was predicted (24), binding did not
occur at the exposed GTP binding site but instead 8 Å from it in
a site occupied in the apoenzyme by the small -helix A at the
tip of the fingertip 1 loop (Fig. 1). This loop anchors the
fingers to the thumb in the apoenzyme and opens in the direc-
tion of the solvent, becoming partially disordered in the inhib-
itor-bound structures with no electron density present for res-
idues 22–35 (Fig. 1). Electron density was also missing for
residues 148–152, part of the fingertip 2 loop that is adjacent
to the 1 loop and also connects the fingers and thumb (Fig. 1).
This region is already flexible in the C55 apostructure (9) but
is completely disordered in the inhibited structures, presum-
ably because of the lack of stabilization provided in the apoen-
zyme by the interaction between 2 Val-147 and 1 Met-36.
Another consequence of the displacement of -helix A and the
resulting weaker interaction between the thumb and fingers is
a slight opening of the polymerase. Indeed, when the palm and
thumb domains of the inhibited structure and the apostructure
are superimposed, we observed a rigid body rotation of the
fingers of 2–4° in a clockwise direction with respect to the
palm. Furthermore, the differences in C positions in the fin-
gers domain varied between 0.5 and 2.1 Å (Fig. 1B). It cannot
be excluded that the rearrangement of the polymerase domains
may have been limited in the crystals by packing interactions
and thus could be even larger in solution. Indeed, crystals could
be soaked in the presence of the inhibitor only for a relatively
short amount of time. An opening of the polymerase, following
inhibitor binding, might prevent either the correct positioning
of RNA and NTPs required for catalysis or the translocation of
the template and product.
Inhibitor-Enzyme Interactions—Despite having a different
indole N-acetyl substituent (Table I) the two inhibitors bind
almost identically to the polymerase (Fig. 2A). In fact only two
carbon atoms of the N-acetyl substituent are in van der Waals
contact distance with the backbone carbonyl oxygen atoms of
Leu-492 and Gly-493 (Fig. 2B), explaining the similar binding
modes and IC50 values for the two molecules (Table I).
The inhibitor-polymerase interaction is mainly hydrophobic.
The only exception is a salt bridge formed by the carboxylate
group of the inhibitor and the guanidinium group of Arg-503.
Plausibly, Arg-503 and the proximal His-428 side chains create
a positive electrostatic potential favorable for the binding of
acidic ligands (Fig. 2B). The cyclohexyl and the phenyl ring
substituents likely contribute to most of the binding energy by
filling two closely spaced pockets of the binding site. The side
chains of Leu-392, Ala-395, Thr-399, Ile-424, Leu-425, His-428,
and Phe-429 form a deep pocket, filled almost completely by the
cyclohexyl group of the inhibitor, whereas the Val-37, Leu-392,
Ala-393, Ala-396, Leu-492, and Val-494 side chains form a
narrower pocket occupied by the inhibitor phenyl ring (Fig.
2B). Interestingly, none of these residues changed conforma-
tion compared with the apoprotein. The indole core bridges
the two groups and also contributes both in filling the pockets
and in the interaction with the protein. One side of the indole
moiety points toward the pocket interior and interacts with
the Val-494 and Trp-500 side chains, whereas the other side
makes van der Waals contacts with the exposed Pro-495
pyrrol ring on the external lower side of the pocket (Fig. 2B).
The latter interaction likely explains the lack of inhibition by
this class of compounds of the NS5B P495L point mutant
(Table I) (24).
The structures suggest several ways to improve the po-
tency of this class of inhibitors (Fig. 2B). In the direction
perpendicular to the plane of the indole moiety the occupancy
of the pocket is not complete, and slightly bulkier moieties
may increase the contact area by approaching Val-494. Sub-
stituents inserted at the para-position of the phenyl ring
could extend into a protein hydrophobic cleft (designated as
“a” in Fig. 2B), significantly increasing the surface contact
area. The N-acetamide substituent could be modified to form
hydrogen bonds with the backbone oxygens of Leu-492 and
Gly-493. Finally, a larger group could substitute for one of
the carboxylate oxygens, so as to extend the inhibitor into a
second hydrophobic region (designated as “b” in Fig. 2B),
while keeping with the other oxygen the polar interaction
with the side chain of Arg-503 (Fig. 2, A and B). In agreement
with this hypothesis, a structurally related indole-scaffolded
inhibitor, containing the same cyclohexyl and phenyl sub-
stituents and an additional elongated amide extension in this
position, inhibits the NS5B polymerase with a subnanomolar
IC50.
2
Indole-based NNIs and Other Small Molecule Binding
Sites—Comparison of the NS5B-GTP complex structure (21)
with our structures shows that the binding sites for GTP and
for the indole-based inhibitors are close in space but clearly
distinct. The GTP molecule lies on a shallow surface in prox-
imity to the fingertip -helix A, whereas the inhibitor fills the
pocket occupied in the apoenzyme by the same -helix (Fig. 2,
A and C). Moreover, GTP binding is not associated with any
2 S. Harper, unpublished data.
FIG. 1. Conformational changes in HCV NS5B associated with inhibitor binding. A, ribbon diagram of the inhibited structure. Fingers,
palm, and thumb domains are colored cyan, red, and green, respectively. The inhibitor (compound 1) is shown in stick representation and colored
magenta. The GTP molecule (dark blue), as revealed by previous structural work (21), and two Mn2 ions (magenta spheres) in the catalytic site
are also shown. The metal ions are coordinated by Asp-220, Asp-318, Asp-319, and several water molecules, but only Asp-220 is shown. Disordered
regions are shown as dashed black lines. C-ter, C terminus; N-ter, N terminus. B, the C55 apostructure (9) (colored as in A) superimposed on the
inhibited structure (gray). Figs. 1–3 were generated with PyMOL (DeLano Scientific).
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protein conformational change (21), whereas inhibitor binding
requires a displacement of the -helix A and part of the 1 loop
(Fig. 2, C and D). However, GTP and inhibitors make some
common interactions with polymerase atoms (Fig. 2, B and C).
Both molecules are at van der Waals contact distances with
Pro-495, although they lie on opposite sides of the pyrrol ring.
Further, both molecules interact with the Arg-503 side chain;
the GTP molecule establishes one water-mediated hydrogen
bond, whereas the inhibitor forms a salt bridge via its carbox-
ylate group (Fig. 2, B and C). Interestingly, in the NS5B-GTP
complex the ribose moiety of GTP hydrogen bonds the guani-
dinium group of Arg-32 (Fig. 2C). This interaction may contrib-
ute to tightening the association of the fingertip 1 loop with
the thumb and could disfavor the opening of the loop and
consequently the access of the inhibitor to its binding site.
Together, the interaction with common residues and between
Arg-32 and GTP provides an explanation for the antagonistic
effect that high concentrations of GTP have on polymerase
inhibition by this class of compounds (24).
The binding site for the indole-based inhibitors is also dis-
tinct from the binding site for another group of NNIs based on
thiophene, phenylalanine, or dihydropyranone scaffolds. These
compounds bind to a common site on an elongated hydrophobic
cleft in the thumb domain near the C terminus of the polymer-
ase (Fig. 3A) (21–23, 26). Although the binding sites for this
group of compounds and for the indole-based inhibitors are 14
Å apart, they reside on opposite sides of the thumb domain
helix Q, which in turn contacts helices S and T (Fig. 3B). Thus,
it is conceivable that these two distinct inhibitor binding sites
are functionally linked through these secondary structural el-
ements. This hypothesis is supported by recent structures of
the 2a polymerase alone and bound to two thiophene-based
NNIs (22). In this study the tip of the 2a polymerase 1 loop
was shown to adopt two different conformations, helical and
-hairpin-like. The -helical conformation was associated with
a closed polymerase structure similar to the 1b apostructure,
whereas in the -hairpin-like conformation the polymerase
adopted a more opened structure (22). Interestingly, the inhib-
itors could bind only to the closed form of the enzyme and
induced a transition to the opened conformation. Thus, al-
though this study did not explain how inhibitor binding would
trigger these conformational changes, the results suggest that
these inhibitors may act by causing a perturbation of the
interaction between the fingertip 1 loop and the thumb
domain and simultaneously locking the enzyme in an opened
FIG. 3. Two allosteric inhibitor binding sites in the thumb
domain. A, ribbon diagram of our inhibited structure with compound 1
(magenta stick) superimposed to the 1b polymerase structure bound to
phenylalanine-based inhibitor (26). For this structure only the inhibitor
is shown (orange stick). The color coding is as in Fig. 1A. B, close-up
view of the thumb domain with secondary structural elements, helices
Q, S, and T, close to the two inhibitor binding sites (compound 1,
magenta stick, our structure; and an NNI having a phenylalanine
scaffold, (orange stick) (26).
FIG. 2. Inhibitor binding site in the
thumb domain. This view is obtained
after a roughly 180° clockwise rotation of
the view shown in Fig. 1A. Protein resi-
dues are drawn in stick representation.
Red, oxygen; blue, nitrogen; green, car-
bon. A, superposition of the crystal struc-
tures with compounds 1 (magenta) and 2
(atom color coding: red, oxygen; blue, ni-
trogen; yellow, carbon). B, residues in-
volved in inhibitor binding and compound
1 (color coding for atoms as described in
A). Val-37 from the fingers domain also
makes hydrophobic interaction with the
inhibitor phenyl ring but is not shown
here. Polar interactions are shown as
dashed black lines. Yellow letters a and b
indicate regions that might be explored
for the generation of more potent com-
pounds. C, GTP binding site in the thumb
domain as revealed by Ref. 21. The color
coding for the GTP molecule atoms is: red,
oxygen; blue, nitrogen; yellow, carbon;
magenta, phosphate. Main chains for res-
idues 18–36 from the fingers are shown
as a cyan coil. D, superposition of the
apoC55 structure (9) with the inhibited
structure (compound 1). The main chain
backbone atoms for residues 18–36 are
shown as a gray coil. Leu-30 (L30) and
Leu-31 (L31) (green) from -helix A and
compound 1 (magenta) are also shown.
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“inactive” conformation (22). Therefore, even if these two
classes of NNIs bind to sites located in different regions of the
thumb, they may ultimately inhibit the polymerase by a
common mechanism.
The Role of the Fingertip -Helix A—The structures of the
inhibited polymerase complexes reported here imply that in the
apoenzyme the 1 loop is conformationally flexible allowing
access of the indole-based inhibitors to the otherwise buried
binding site. In the apostructure, the Leu-30 and Leu-31 side
chains from -helix A only partially fill the pockets occupied by
the inhibitor cyclohexyl and phenyl substituents, respectively
(Fig. 2D). In fact, not only are the two side chains smaller than
the two inhibitor cyclic substituents, but also, because of con-
straints imposed by the -helical structure in this region of the
1 loop, they protrude less deeply into the corresponding pock-
ets. It is attractive to speculate that a suboptimal anchoring of
fingers to the thumb established by -helix A might provide the
polymerase with the conformational flexibility required during
the different steps of RNA synthesis. The flexibility of the 1
loop and its role in holding the thumb and fingers together are
further supported by the recently solved structures of the
polymerase genotype 2a (22) (see above).
The high sequence conservation among HCV genotypes of
the region displaced by the inhibitor, as well as of residues
forming the inhibitor binding pockets (Fig. 4), supports an
essential function of -helix A-thumb domain interaction for
NS5B activity. Consistently, mutation of Leu-30 to Ser or Arg
results in an inactive enzyme (33). Helical regions at the tip of
fingertip loops connecting the fingers and thumb are present in
other viral RdRps (12–17, 19). The similarities in the structure
and enzymatic mechanism (34) between NS5B and these poly-
merases suggest that flexibility of the fingertip loops could also
be a feature of some of these RdRps, and inhibitor binding sites
similar to the one described here could also be available for
them.
Conclusion—Previous biochemical studies have suggested
that the HCV polymerase catalyzes RNA synthesis through an
ordered stepwise mechanism (24). The polymerase-RNA tem-
plate complex is first formed rapidly. Second, a productive
enzyme elongation complex is formed more slowly (24). The
FIG. 5. Schematic mechanism of in-
hibition by indole-based compounds.
The inhibitor is depicted as a yellow circle.
The fingers, palm, and thumb domains
are shown as spheres and colored as in
Fig. 1A.
FIG. 4. Partial sequence alignment
of representative HCV polymerase
sequences from the most common
genotypes: 1a, 1b (these structures),
2a, 2b, 2c, and 3a. Numbers to the left of
the genotypes correspond to the accession
numbers from GenBankTM. Strictly con-
served residues are shown in black on a
pink background. Non-conserved residues
are shown in red. A, alignment of residues
displaced by the inhibitor. B, alignment of
residues interacting with the inhibitor.
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indole-based inhibitors, similar to what has been observed for
the structurally related benzimidazole-based inhibitors (24),
bind and inhibit NS5B only prior to formation of the latter
complex.3
Several pieces of evidence support our structure as a genuine
model for the high affinity indole-based inhibitor polymerase
interaction. First, the competition between these inhibitors and
GTP and the lack of inhibitor binding of the point mutant
P495L are in agreement with the structures here reported.
Second, this class of inhibitors bind to the apoenzyme and to
the initial template-enzyme complexes with similar affinities
(24) suggesting that they bind similarly to both forms of the
polymerase. Third, the almost perfect fit of the cyclohexyl and
phenyl rings into the -helix A-derived binding site pockets is
suggestive of a high affinity interaction. Fourth, although our
inhibited structure revealed a rigid body rotation of the fingers
relative to the palm and thumb domains, we did not observe
any changes in the structure of the thumb domain itself. This
suggests that the details of the interaction between thumb and
inhibitor would be preserved even if in solution the polymerase
adopted a more opened conformation when bound to the
inhibitor.
When the published biochemical data are combined with the
structures reported here, a model for the NS5B inhibition by
the indole-based compounds can be proposed (Fig. 5). Before
formation of a productive initiation complex, the fingertip -he-
lix A is flexible and opens toward the solvent allowing binding
of the inhibitor. After binding, the connection between the
fingers and thumb domains is, at least partially, abrogated,
and the 1 loop can no longer mediate the concerted rearrange-
ment of the polymerase domains needed for formation of a
productive RNA-enzyme complex. Interestingly, when added
after formation of the productive complex, the inhibitor did not
bind or inhibit (24, 25) suggesting that during elongation either
the binding site is not available because of a tighter interaction
between the 1 fingertip residues and thumb or because the
polymerase has assumed a somewhat different shape.
In conclusion the structures reported here have identified a
novel allosteric inhibitor binding site on the HCV NS5B polym-
erase that could not be predicted based on previous work and
revealed the mechanism of inhibition of a new class of HCV
NNIs. Moreover, the structures have shown the details of the
interactions established by the inhibitor suggesting ways to
improve the potency for this class of molecules. Finally, our
study further supports a model whereby the polymerase 1
loop regulates the coordinated movements of the fingers and
thumb during the polymerase reaction cycle.
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